Hepatotoxicity is a phenotype of liver cell injury due to a multitude of causes including drugs, toxins, herbal and dietary supplements, and other agents. The goal of the AASLD Hepatotoxicity SIG is to promote and encourage research, education, and awareness regarding human hepatotoxicity. As such, individuals with any of the following interests and expertise are encouraged to partake in SIG activities.

  • Drug hepatotoxicity
  • Animal and cell culture models of hepatotoxicity
  • Intrinsic and extrinsic mechanisms of hepatocyte death
  • Pharmacogenomics
  • Pharmacoepidemiology
  • Herbal and dietary supplement induced liver injury
  • Regulatory issues involving drugs and HDS products
  • Acute Liver failure
  • Liver transplantation
  • Treatments for acute and chronic hepatotoxicity
  • Liver histopathology
  • Adverse drug events
  • Drug pharmacokinetics and pharmacodynamics
  • Nomenclature of hepatotoxicity

SIG Leadership

Wen-Xing Ding, MD, PhD, FAASLD

Lily Dara, MD

Ayako Suzuki, MD, PhD, MSC

Staff Liaisons
Patricia Marshall
Akuender Dot
Linda Howard

Steering Committee Members
Melissa Palmer, MD, FAASLD
David Kleiner, MD, PhD
Mitchell McGill, PhD
James P. Luyendyk, PhD
Christopher Koh, MD, MHSc FAASLD
Layla Shojaie, M.D.
Burcin Ekser, MD, PhD